Vanda Pharmaceuticals Inc. (VNDA)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 533
- Market Cap
- $302M
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
SentiSense also tracks daily options readings for Vanda Pharmaceuticals Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Vanda Pharmaceuticals Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.